Arcturus Therapeutics (ARCT) Prices 3.26M Share Common Offering at $53/Sh

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) today announced the pricing of an underwritten public offering of 3,264,151 shares of its common stock at a public offering price of $53.00 per share. The gross proceeds of the offering to the Company are expected to be approximately $173.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, the Company granted the underwriters a thirty-day option to purchase up to an additional 489,622 shares of common stock at the public offering price, less underwriting discounts and commissions.

The closing of the offering is expected to occur on or about July 31, 2020, subject to the satisfaction of customary closing conditions.

Citigroup, Guggenheim Securities and Barclays are acting as joint book-running managers for the offering. Baird, B. Riley FBR and H.C. Wainwright & Co. are acting as co-lead managers for the offering. Ladenburg Thalmann is acting as co-manager for the offering.

The Company intends to use the net proceeds of the offering to develop, test and manufacture the Company’s LUNAR-COV19 vaccine candidate and to continue clinical development of LUNAR-OTC; to advance the Company’s LUNAR-CF, LUNAR-CV and LUNAR-FLU preclinical programs into clinical development; to fund early research and development of novel and proprietary RNA medicines; and for general corporate and working capital purposes.

You May Also Be Interested In

• CervoMed closes $10M stock offering at $4.00 per share
• RedHill Biopharma closes $6M private placement with warrant upside
• Booz Allen to buy Ultra Mission Solutions for $720 million